Views & Analysis | Perspectives on pharma industry issues

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Articles

An insight into generic patent strategies

In the first of a series of interviews we will be featuring on pharmaphorum, Paul Tunnah spoke with Pam Politis to talk about generic patent strategies. pharmaphorum caught up with Pam Politis, Senior Patent Attorney for Endo Pharmaceuticals in the US...

Articles

What did you get out of the 2010 Annual Meeting of the Ameri...

Following the close of the world's largest gathering of cancer experts, four expert attendees from Kantar Health summarise what they learnt at the American Society of Clinical Oncology (ASCO) 2010 meeting. This major annual event is on a scale that is hard to imagine. Comprising 28,000 members...

Articles

Differentiating novelty in the complex oncology market

In the wake of a mass of oncology news from the ASCO conference, Maie Gall presents a case for changes in the way differentiation for novel assets is communicated in cancer. As another American Society of Clinical Oncology (ASCO) meeting closes with an incredible amount of new compounds, new products, new indications and new combinations...

Sales & Marketing

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.